Pune, Maharastra -- (SBWIRE) -- 11/23/2015 -- The global hormone replacement therapy market is expected to witness some trends during the forecast period, which would be major influencers for market dynamics. One such trend is the paradigm shift toward non-hormonal therapies such as clonidine, venlafaxine, fluoxetine, and gabapentin to reduce symptoms of menopause, which is a paradigm shift from hormone-based therapies.
According to the Global Hormone Replacement Therapy Market 2015-2019 report, one of the important drivers in the global hormone replacement therapy market is significant current unmet needs in the market to encourage vendors to enter it. The current treatment options are incapable of meeting the market requirements due to their lower safety profiles, thereby leaving large unmet needs in this market. The requirement for new treatment options with better safety results is huge.
An overview of the hormone replacement therapy market
Hormone replacement therapy involves the replacement of the hormones in the body whose levels have become low, in case of women nearing menopause or patient with growth hormone deficiency due to conditions such as dwarfism. At present, the combination of drugs are used to treat the conditions, which are known to have a better safety and efficacy parameter. Unmet medical needs is one of the major drivers influencing the growth of the market. Therefore, the need for new treatment options with better safety results to accommodate the current unmet need is huge.
In 2014, the Americas dominated the market, where the majority of the contribution was from the US, and this trend is expected to continue during the forecast period. However, the market in the APAC region is witnessing a rapid growth, hence, there is a vast opportunity for vendors to venture into this region. The expects the global hormone replacement therapy market to grow at a moderate rate, posting a CAGR of over 2% during the forecast period. Order a Copy of Report at http://www.rnrmarketresearch.com/contacts/purchase?rname=430659.
Segmentation of the hormone replacement therapy market by type of hormonal therapy: Estrogen replacement therapy and Growth hormone replacement therapy.
With a market share of more than 60% the estrogen replacement therapy segment dominate the hormone replacement therapy market. Estrogen replacement therapy is a type of therapy in which estrogen hormones are commonly used to treat the symptoms of menopause. It helps in the reduction of short-term changes of menopause such as hot flashes, disturbed sleep, and vaginal dryness.
Segmentation of the hormone replacement therapy market by route of administration: Oral, Parenteral, Transdermal
The oral route of administration is a sub-division of enteral administration and is regarded as one of the safest and most preferred routes of drug administration. Some of the drug that are administered orally are Premarin and Estrace.
Further, the report states that one of the major challenges is the high cost of hormone replacement therapy, which hinders its acceptability among patients. Many patients do not have the required budget to invest in high-cost treatment options, and it can result in treatment withdrawal.
The following companies are the key players in the Global Harmone Replacement Therapy Market: F. Hoffmann-La Roche, Merck Serono, Novartis, Novo Nordisk and Pfizer
Other Prominent Vendors in the market are: Abbott Laboratories, Amgen, ANI Pharmaceuticals, Bayer, Eli Lilly, Hisamitsu Pharmaceutical, Ipsen, Merck, Mylan Laboratories, Orion, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries, and TherapeuticsMD.
Single User License Copy of the Report is US $2500, get DISCOUNT at http://www.rnrmarketresearch.com/contacts/discount?rname=430659.
About RnRMarketResearch.com
RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.